Therapeutically active compounds and their methods of use

Inventors

Cianchetta, Giovanni • DELABARRE, BYRON • Popovici-Muller, Janeta • Salituro, Francesco G. • Saunders, Jeffrey O. • Travins, Jeremy • Yan, Shunqi • Guo, Tao • Zhang, Li

Assignees

Servier Pharmaceuticals LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11505538-B1

Patent

Publication Date

2022-11-22

Expiration Date


Abstract

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

Core Innovation

The disclosed subject matter provides substituted heteroaromatic compounds, including substituted 1,3,5-triazine-2,4-diamine derivatives of Formulas I and II, for inhibiting mutant IDH2. Disclosed embodiments encompass phenyl-, pyridyl-, pyrimidinyl-, and amino-substituted analogs bearing varied halogen, fluoro, chloro, trifluoromethyl, cyano, alkoxy, sulfonyl, hydroxy, and heterocyclic substituents. The disclosure also identifies stereoisomeric, isotopic, salt, hydrate, and prodrug forms, supported by representative compounds, analytical data, and enzymatic inhibition data.

The disclosed compounds inhibit mutant IDH2 with alpha-hydroxyl neoactivity that catalyzes the NADPH-dependent conversion of alpha-ketoglutarate to R(-)-2-hydroxyglutarate, targeting variants such as R140 and R172. The subject matter is directed to treating IDH2-mutant cancers, where treatment response is optionally monitored through 2-hydroxyglutarate levels. Because the background, summary, and abstract sections are omitted from the supplied content, the problem being solved is not explicitly described in patent.

Claims Coverage

The supplied claims identify one independent claim directed to a compound or a pharmaceutically acceptable salt or hydrate thereof, with five principal inventive features across the claims.

Substituted triazine compound and pharmaceutically acceptable forms

The independent claim recites a compound, or a pharmaceutically acceptable salt or hydrate thereof, wherein the compound structure is not rendered in the provided claim text.

Pharmaceutical composition

A dependent claim covers a pharmaceutical composition comprising the claimed compound and a pharmaceutically acceptable carrier.

Treatment of IDH2-mutation-characterized cancer

A dependent claim covers treating cancer characterized by an IDH2 mutation that enables NADPH-dependent conversion of ketoglutarate to R(-)-2-hydroxyglutarate by administering the claimed compound.

Specified IDH2 mutations and cancer types

Dependent claims specify IDH2 R140Q or R172K mutations and identify cancer types including glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, cholangiocarcinomas, and angioimmunoblastic non-Hodgkin's lymphoma.

Administration of a second therapeutic agent

A dependent claim provides for administering a second therapeutic agent useful in treating cancer.

The claims cover the compound and its pharmaceutically acceptable salt or hydrate, a pharmaceutical composition containing the compound, and methods of treating specified IDH2-mutation-characterized cancers optionally in combination with a second therapeutic agent.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Treatment of cancer characterized by an IDH2 mutation that enables NADPH-dependent conversion of ketoglutarate to R(-)-2-hydroxyglutarate, including cancers with IDH2 R140, R140Q, R172, or R172K mutations such as glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, cholangiocarcinomas, and angioimmunoblastic non-Hodgkin's lymphoma.

Pharmaceutical compositions comprising the claimed compound and a pharmaceutically acceptable carrier.

Cancer treatment regimens comprising co-administration of the claimed compound with a second therapeutic agent useful in treating cancer.

Monitoring treatment response through 2-hydroxyglutarate levels.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.